Spectral Medical announces in a press release on April 14th 2020 that the FDA (US Food and Drug Administration) has approved an Investigational Device Exemption (IDE) for Toraymyxin to treat COVID-19 patients suffering from septic shock.
- Toraymyxin has successfully been used for treatment in COVID-19 patients in the U.S., Japan and Italy
- IDE approval provides access to Toraymyxin to help clinicians treat COVID-19 patients in septic shock
- Publications available in Literature have demonstrated that endotoxin neutralization and activated immune cell apheresis by Toraymyxin can decrease cytokine storm, improve lung function and facilitate weaning from ventilator in patients affected by viral infection who developed severe ARF (Acute Respiratory Faliure).